Market Overview

Valeant Pharmaceuticals Announces Management Change

Related VRX
Valeant's Stock Drops, Then Recovers, Following False Report Of FBI Raid
Early Global News: Record Online Sales, 400% Jump In Tinder Users, China Experiences Worst Drop In Months
Valeant's Eastern Front (Seeking Alpha)

Valeant Pharmaceuticals International (NYSE: VRX) announced today that Rajiv De Silva, Valeant's President and Chief Operating Officer of Specialty Pharmaceuticals, will be leaving the Company to pursue other interests. Mr. De Silva will remain with the Company through the remainder of the year, when the integration planning efforts related to its announced acquisition of Medicis Pharmaceutical Corporation (NYSE: MRX) are expected to have been completed.  Mr. De Silva will be a core member of the team leading these integration planning efforts. In addition, we expect that a number of Medicis executives would accept positions with Valeant after the acquisition has been completed.

"The Board of Directors and I appreciate the significant contributions Rajiv has made these past few years since joining me on this journey to create a new pharmaceutical operating model," said J. Michael Pearson, chairman and chief executive officer.  "Under Rajiv's leadership, we have become a leader in the U.S. dermatology space and transformed our operations in Canada and Australia. And although his leadership will be missed, the company has created and developed a strong management team with Rajiv's assistance that I am confident will lead us successfully

See full press release

Posted-In: News Asset Sales Management


Related Articles (MRX + VRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters